Swiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Swiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology.